Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT02733419 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Enfuvirtide
DRUG: Optimized background antiretroviral regimen (OB)

Sponsor

Hoffmann-La Roche